Cencora reports fiscal results November 4. Cencora stock falls 1.26 percent

Published on 10/27/2026 at 16:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora lifted fiscal 2026 adjusted EPS guidance to USD 17.75-17.95. Cencora stock costs EUR 293.65 on October 27, 2026, 1.26 percent below Xetra close.

Guidance and price position

Cencora plans to release fiscal fourth-quarter results on November 4, 2026.
Fiscal 2026 adjusted earnings per share guidance stands at USD 17.75-17.95.
Cencora stock costs EUR 293.65 at Lang & Schwarz on October 27, 2026 at 4:46 p.m. CEST, 1.26 percent below the Xetra close.
The 52-week NYSE range is USD 244.82 to USD 377.54.

Cencora Inc., US03073E1055, Illustration mit AI erstellt.

Cencora Inc. (ISIN US03073E1055) plans to release its fiscal fourth-quarter results on November 4, 2026, before trading opens on the New York Stock Exchange, according to Business Wire. The date gives investors the next scheduled test of the company outlook. At Lang & Schwarz, the stock was trading at EUR 293.65 on October 27, 2026 at 4:46 p.m. CEST, 1.26 percent below the Xetra close of October 26, 2026 at EUR 297.40.

Guidance reaches USD 17.95

Cencora raised its fiscal 2026 adjusted earnings per share guidance to USD 17.75-17.95 from USD 17.70-17.90, as management discussed the third-quarter performance on October 8, 2026. Benzinga reported that adjusted operating income grew 17 percent in the fiscal third quarter, while adjusted earnings per share increased 12 percent.

Revenue grew 5.1 percent

For the fiscal third quarter ended June 30, 2026, revenue increased 5.1 percent year over year to USD 84.8 billion, while GAAP diluted earnings per share rose to USD 3.94 from USD 3.52. The figures came with the company report carried by Business Wire.

Stock remains below its high

The NYSE 52-week range was USD 244.82 to USD 377.54 as of October 20, 2026. The lower euro quotation therefore sits below the documented dollar high, but the currencies are not combined in one performance calculation. MarketBeat listed a USD 64.9 billion market capitalization and a 25.27 price-to-earnings ratio on October 20, 2026.

November 4 sets the date

The earnings release is scheduled for before the NYSE open on November 4, 2026, followed by a conference call at 8:30 a.m. ET, according to Business Wire. The scheduled release will put the adjusted earnings range, revenue growth and specialty healthcare execution on the same timetable.

Price holds the market frame

Cencora combines pharmaceutical distribution with commercialization, patient-access and pharmacy solutions. Its fiscal third-quarter revenue of USD 84.8 billion and adjusted earnings per share guidance of USD 17.75-17.95 provide the key operating figures ahead of the November report. The stock stood at EUR 293.65 at Lang & Schwarz on October 27, 2026 at 4:46 p.m. CEST, 1.26 percent below the Xetra close of October 26, 2026 at EUR 297.40. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.